NEW YORK, May 02, 2025 (GLOBE NEWSWIRE) -- Silvercrest Asset Management Group Inc. (NASDAQ: SAMG) announced today it will host a teleconference at 8:30 am Eastern Time on May 9, 2025, to discuss the company’s financial results for the first quarter ended March 31, 2025. A news release containing the results will be issued before the open of the U.S. equity markets and will be available on http://ir.silvercrestgroup.com/.Chairman, Chief Executive Officer and President Richard R. Hough III and Chief Financial ...

SAN CARLOS, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its first quarter 2025 financial results and corporate updates on Thursday, May 8, 2025. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update on May 8, 2025 at 4:30 p.m. ET. ...

Core Insights - MercadoLibre, Inc. will release its financial results for the first fiscal quarter ending March 31, 2025, on May 7, 2025 [1] - The company will host a video conference, conference call, and audio webcast on the same day at 5:00 p.m. Eastern Time [1] Company Overview - MercadoLibre is the largest online commerce ecosystem in Latin America, based on unique visitors and processed orders, and is a leading fintech platform in the region [5] - The company operates in 18 countries, including Argentina, Brazil, Mexico, Colombia, Chile, and Peru [5] E-commerce and Fintech Services - MercadoLibre provides a robust and safe environment for buyers and sellers, fostering a large e-commerce community in Latin America, which has a population of over 650 million [6] - The company offers world-class technological and commercial solutions tailored to the cultural and geographic challenges of digital commerce in Latin America [6] - Through its fintech platform, MercadoPago, the company provides a comprehensive set of financial technology services, including digital accounts, online payments, insurance, savings, investments, and credit lines for individuals and merchants [7]

Core Viewpoint - Navios Maritime Partners L.P. will host a conference call to discuss its Q1 2025 earnings results on May 7, 2025, at 8:30 am ET [1][2]. Group 1: Conference Call Details - The conference call will take place on May 7, 2025, at 8:30 am ET, where senior management will provide highlights and commentary on the earnings results for the first quarter ended March 31, 2025 [1]. - A supplemental slide presentation will be available on the Navios Partners website at 8:00 am ET on the day of the call [2]. - The US dial-in number for the call is +1.800.445.7795, and the international dial-in number is +1.785.424.1699, with a conference ID of NMMQ125 [2]. Group 2: Replay and Webcast Information - The conference call replay will be available two hours after the live call and will remain accessible for one week [2]. - The US replay dial-in number is +1.800.839.8292, and the international replay dial-in number is +1.402.220.6069 [2]. - The call will be simultaneously webcast and archived on the Navios Partners website for two weeks following the call [2]. Group 3: Company Overview - Navios Maritime Partners L.P. is an international owner and operator of dry cargo and tanker vessels [3].

Core Viewpoint - Capital Clean Energy Carriers Corp. (CCEC) is set to release its financial results for the first quarter ended March 31, 2025, before the NASDAQ market opens on May 8, 2025, followed by an interactive conference call to discuss these results [1]. Company Overview - Capital Clean Energy Carriers Corp. (NASDAQ: CCEC) is an international shipping company specializing in gas carriage solutions, focusing on energy transition [5]. - The company's fleet includes 15 high specification vessels, comprising 12 latest generation LNG carriers and three legacy Neo-Panamax container vessels [5]. - CCEC has six additional latest generation LNG carriers, six dual-fuel medium gas carriers, and four handy liquid CO2/multi-gas carriers under construction, scheduled for delivery in 2026 and 2027 [5].

Core Viewpoint - Longeveron Inc. is set to report its first quarter 2025 financial results and provide a business update on May 8, 2025, after U.S. market close, followed by a conference call and webcast [1] Company Overview - Longeveron Inc. is a clinical stage biotechnology company focused on developing regenerative medicines to meet unmet medical needs [3] - The company's lead investigational product is laromestrocel (Lomecel-B™), an allogeneic mesenchymal stem cell therapy derived from the bone marrow of young, healthy adult donors [3] - Laromestrocel has multiple potential mechanisms of action, including pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair effects, with applications across various disease areas [3] Pipeline and FDA Designations - Longeveron is pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer's disease (AD), and aging-related frailty [3] - The HLHS program has received three FDA designations: Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation [3] - The AD program has received two important FDA designations: Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation [3]

Core Viewpoint - Alvotech is set to release its financial results for Q1 2025 on May 7, 2025, and will hold a conference call on May 8, 2025, to discuss these results and recent business highlights [1]. Company Overview - Alvotech is a biotech company focused on developing and manufacturing biosimilar medicines globally, aiming to be a leader in the biosimilar market by providing high-quality, cost-effective products [3]. - The company has two approved biosimilars, Humira® (adalimumab) and Stelara® (ustekinumab), which are marketed in multiple global markets [3]. - Alvotech's development pipeline includes nine disclosed biosimilar candidates targeting various conditions such as autoimmune disorders, eye disorders, osteoporosis, respiratory diseases, and cancer [3]. - The company has established a network of strategic commercial partnerships across the United States, Europe, Japan, China, and other regions, enhancing its global reach [3]. Investor Relations - Information regarding the webcast and conference call participation is available on Alvotech's investor website, with the webcast being archived for 90 days post-event [2]. - The company encourages engagement through its investor portal and social media platforms [4].

REYKJAVIK, Iceland, May 02, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for the first quarter ended March 31, 2025, after U.S. markets close on Wednesday, May 7, 2025. Alvotech will also conduct a conference call with analysts to present the financial results and recent business highlights on Thursday, May 8, 2025, at 8:00 am EDT ...

Amazon.com Inc AMZN reported stronger-than-expected first-quarter financial results after market close Thursday.Amazon.com reported first-quarter net sales of $155.7 billion, up 9% year-over-year. The net sales beat a Street consensus estimate of $155.04 billion according to data from Benzinga Pro. The company reported first-quarter earnings per share of $1.59, beating a Street consensus estimate of $1.36.“We’re pleased with the start to 2025, especially our pace of innovation and progress in continuing to ...

Company Overview - Ocugen, Inc. is a pioneering biotechnology leader focused on gene therapies for blindness diseases, utilizing a breakthrough modifier gene therapy platform to address significant unmet medical needs for large patient populations [3]. Upcoming Events - Ocugen will host a conference call and live webcast to discuss its first quarter 2025 financial results and provide a business update on May 9, 2025, at 8:30 a.m. ET [1]. - A pre-market earnings announcement will be issued on the same day, with dial-in numbers provided for U.S. and international callers [2]. Product Development - The company is developing programs for inherited retinal diseases and blindness diseases affecting millions globally, including retinitis pigmentosa, Stargardt disease, and geographic atrophy [3].